Contatti | Lavora con noi | Richiedi un preventivo| Download
HIGHLIGTHS IN ADVANCED RENAL CELL CARCINOMA MANAGEMENT
24 febbraio 2012
Sede del Corso:
DOMUS NOVA BETHLEM - Roma
Director: Camillo Porta
ABSTRACT SIGNIFICATIVI
Dottor Procopio
The management of metastatic renal cell carcinoma (mRCC) has been revolutionized with targeted therapies (TTs), superseding cytokine therapy (interferon-α [IFN-α] and interleukin-2 [IL-2]). Indeed, because of the number of therapies now available, the identification of prognostic factors plays an important role in the clinical management of the advanced disease
Prognostic factors allow stratification of patients based on risk of death related to cancer and they are important indicators of the evolution or progression of the disease. Moreover, these allow a homogeneous stratification of patients in clinical trials, avoiding the identification of any group in which a TT has the greatest activity, which would constitute a selection In contrast to an organ-confined tumor, the pathologic characteristics of metastatic disease are not sufficient to define the prognosis, and some elements, other than possible changes in biochemical parameters, such as the spread of disease and the patient’s general performance status (PS), need to be evaluated In the cytokine era, the most commonly used prognostic criteria have been those developed by Motzer, assessing 670 patients enrolled in clinical trials of immunotherapy and chemotherapy at the Memorial Sloan Kettering Cancer Centre The multivariate analysis has revealed that hemoglobin, serum lactate dehydrogenase, corrected serum calcium level, nephrectomy, and Karnofsky PS were independent risk factors for prediction of survival.
PROGRAMMA
8.30 Registration
8.45 - 11.00 Introduction
C. Porta, Pavia
1 Pathology and genetics SERIE DI RELAZIONI SU TEMA PREORDINATO
Prof. Guido Martignoni
2 Prognostic factors and predictive models in RCC SERIE DI RELAZIONI SU TEMA PREORDINATO
Prof. Vincenzo Ficarra
3 Advances in imaging SERIE DI RELAZIONI SU TEMA PREORDINATO Dr. Alessandro Vercelli (Pavia)
4 Surgical management of RCC SERIE DI RELAZIONI SU TEMA PREORDINATO
Giario Conti
11.00 - 11.30 Coffee Break
11.30 - 13.00
5 Neoadjuvant /adjuvant treatment of advanced RCC SERIE DI RELAZIONI SU TEMA PREORDINATO
Dr. Giuseppe Procopio
6 Therapy options in first line treatment SERIE DI RELAZIONI SU TEMA PREORDINATO
Dr. Roberto Sabbatini
7 Therapy options in second line treatment SERIE DI RELAZIONI SU TEMA PREORDINATO
Dr. Chiara Paglino
13.00 - 14.00 Lunch
14.00 - 16.30
8 Management of toxicities of targeted therapy in mRCC SERIE DI RELAZIONI SU TEMA PREORDINATO
Giacomo Cartenì
9 New Agents for mRCC SERIE DI RELAZIONI SU TEMA PREORDINATO
Cora Sternberg
10 Systemic treatment for non clear cell histology SERIE DI RELAZIONI SU TEMA PREORDINATO
Dr.ssa Alessandra Mosca
11 Evidence-Based Medicine and guidelines SERIE DI RELAZIONI SU TEMA PREORDINATO
Giovanni Pappagallo
12 Clinical cases discussion SERIE DI RELAZIONI SU TEMA PREORDINATO/verifica questionario
Dr.ssa Cristina Masini
16.30 - 17.00 Discussion & Conclusions
Vedi la Brochure